

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)

Mitchell E. REFF et al)

Serial No.: 09/019,441)


Filed: February 5, 1998)

For: GAMMA-1 AND GAMMA-3)
ANTI-HUMAN CD23)
MONOCLONAL ANTIBODIES)
AND USE THEREOF AS)
THERAPEUTICS)

Group Art Unit: 1644

Examiner: M. Dibrino

ATTENTION: BOX SEQUENCE



TRANSMITTAL LETTER

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In complete response to the Office communication concerning the Requirements for
Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence disclosures dated
April 25, 2000, enclosed please find:

- [X] A copy of the "Sequence Listing" in computer readable form in compliance with
37 C.F.R. §§1.823(b) and 1.824.
- [X] A statement that the content of the paper and computer readable copies are the
same as set forth in 37 C.F.R. §1.821(f).

The Commissioner is hereby authorized to charge any additional fees under 37 C.F.R.
§§1.16, 1.17, and 1.21 that may be required by this paper, and to credit any overpayment to Deposit
Account No. 02-4800. A duplicate copy of this paper is enclosed.

Respectfully submitted,

1737 King Street, Suite 500
Alexandria, VA 22314-2756
(703) 836-6620

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

Date: JULY 25, 2000

By Robin L. Teskin

Robin L. Teskin
Registration No. 35,030